GIM
ABBV icon

Greylin Investment Management’s AbbVie ABBV Stock Holding History

Greylin Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-36,685
Closed -$2.07M – 66
2014
Q2 		$2.07M Sell
36,685
-9,265
-20% -$486K 0.5% 26
2014
Q1 		$2.36M Sell
45,950
-43,476
-49% -$2.2M 0.57% 22
2013
Q4 		$4.72M Buy
+89,426
New +$4.4M 1.17% 16

Other funds holding ABBV

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Greylin Investment Management's ABBV Position: Q3 2014 in Review

Greylin Investment Management sold out of AbbVie (ABBV) in Q3 2014, closing a stake of 36,685 shares — an estimated $2.07M sold.

Greylin Investment Management first reported a position in ABBV in Q4 2013 and held it in 3 quarters. The position peaked at $4.72M in Q4 2013. 1,501 funds tracked by Wall St. Rank hold ABBV as of Q3 2014.

  • Greylin Investment Management reported no remaining AbbVie position as of Q3 2014 after selling out during the quarter.
  • Greylin Investment Management sold 36,685 AbbVie shares in Q3 2014, an estimated $2.07M.
  • Greylin Investment Management first reported a position in AbbVie in Q4 2013 and held it in 3 quarters.
  • Greylin Investment Management's AbbVie position peaked at $4.72M in Q4 2013.
  • 1,501 funds tracked by Wall St. Rank held AbbVie as of Q3 2014.

Based on Greylin Investment Management's 13F filing for Q3 2014, filed 12 Nov 2014.